研究者業績
基本情報
- 所属
- 藤田医科大学ばんたね病院 医学部 消化器外科学 病院長・教授
- 学位
- 医学博士(1901年3月 藤田保健衛生大学大学院)
- J-GLOBAL ID
- 200901021819103327
- researchmap会員ID
- 1000170789
- 外部リンク
研究分野
1経歴
10-
2020年2月 - 現在
-
2016年4月 - 現在
-
2016年4月 - 現在
-
2016年4月 - 2020年1月
-
2015年4月 - 2016年3月
論文
469-
Journal of hepato-biliary-pancreatic sciences 2025年3月16日PURPOSE: This study aimed to clarify the current treatment status for biliary tract cancers based on data from the National Clinical Database (NCD) in Japan. METHODS: Total 3895 cases of biliary tract cancers registered in the NCD during 2021 were included. We identified the rates of resection, R0 resection, postoperative complications, and incidences of lymph node metastasis for gallbladder carcinoma, perihilar cholangiocarcinoma, distal bile duct carcinoma, and ampullary carcinoma. RESULTS: The number of biliary tract cancers registered in the NCD during 2021 was 3895 (1775 in extrahepatic bile duct carcinoma, 1422 in gallbladder carcinoma, and 698 in ampullary carcinoma). In gallbladder carcinoma, the resection (89.59%) and R0 resection rates (87.99%) were favorable, and the complication rate (6.05%) was lower than that of others. However, the postoperative complication rate could be higher in T3-T4 cases and when extrahepatic bile duct resection was performed concomitantly. Lymph node metastasis was frequently seen in 12.60% at the No. 13a lymph node. In perihilar cholangiocarcinoma, the R0 resection (69.82%) and complication rates (16.75%) were significantly lower and higher, respectively. In distal cholangiocarcinoma and ampullary carcinoma, metastasis was observed in approximately 2% and 10% of the dissected No. 16b1 para-aortic lymph nodes, respectively. In conclusion, although short-term surgical outcomes for biliary tract cancers in Japan might be acceptable, the significantly lower R0 resection and higher complication rates of perihilar cholangiocarcinomas indicate additional challenges for surgeons in the future and should continue to be monitored by the Japanese Society of Hepatobiliary and Pancreatic Surgery.
-
International Journal for Quality in Health Care mzae108 2024年11月 査読有り
-
Pathology international 2024年9月11日This study aimed to validate the DFS (direct fast scarlet) staining in the diagnosis of EC (eosinophilic colitis). The study included 50 patients with EC and 60 with control colons. Among the 60 control samples, 39 and 21 were collected from the ascending and descending colons, respectively. We compared the median number of eosinophils and frequency of eosinophil degranulation by HE (hematoxylin and eosin) and DFS staining between the EC and control groups. In the right hemi-colon, eosinophil count by HE was useful in distinguishing between EC and control (41.5 vs. 26.0 cells/HPF, p < 0.001), but the ideal cutoff value is 27.5 cells/HPF (high-power field). However, this method is not useful in the left hemi-colon (12.5 vs. 13.0 cells/HPF, p = 0.990). The presence of degranulation by DFS allows us to distinguish between the groups even in the left hemi-colon (58% vs. 5%, p < 0.001). DFS staining also enabled a more accurate determination of degranulation than HE. According to the current standard to diagnose EC (count by HE staining ≥20 cells/HPF), mucosal sampling from left hemi-colon is problematic since the number of eosinophils could not be increased even in EC. Determination of degranulated eosinophils by DFS may potentiate the diagnostic performance even in such conditions.
-
Annals of gastroenterological surgery 8(5) 845-859 2024年9月BACKGROUND: Surgical resection is standard treatment for invasive intraductal papillary mucinous carcinoma (IPMC); however, impact of multidisciplinary treatment on survival including postoperative adjuvant therapy (AT), neoadjuvant therapy (NAT), and treatment for recurrent lesions is unclear. We investigated the effectiveness of multidisciplinary treatment in prolonging survival of patients with invasive IPMC. METHODS: This retrospective multi-institutional study included 1183 patients with invasive IPMC undergoing surgery at 40 academic institutions. We analyzed the effects of AT, NAT, and treatment for recurrence on survival of patients with invasive IPMC. RESULTS: Completion of the planned postoperative AT for 6 months improved the overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) of patients with stage IIB and stage III resected invasive IPMC, elevated preoperative carbohydrate antigen 19-9 level, lymphovascular invasion, perineural invasion, serosal invasion, and lymph node metastasis on un-matched and matched analyses. Of the patients with borderline resectable (BR) invasive IPMC, the OS (p = 0.001), DSS (p = 0.001), and RFS (p = 0.001) of patients undergoing NAT was longer than that of those without on the matched analysis. Of the 484 invasive IPMC patients (40.9%) who developed recurrence after surgery, the OS of 365 patients who received any treatment for recurrence was longer than that of those without treatment (40.6 vs. 22.4 months, p < 0.001). CONCLUSION: Postoperative AT might benefit selected patients with invasive IPMC, especially those at high risk of poor survival. NAT might improve the survivability of BR invasive IPMC. Any treatment for recurrence after surgery for invasive IPMC might improve survival.
-
Fujita medical journal 10(3) 69-74 2024年8月OBJECTIVE: This study was performed to demonstrate the clinical application of duodenum-preserving pancreatic head resection (DPPHR) as a surgical treatment for pancreatic neuroendocrine tumors (PNETs) in terms of both curability and maintenance of postoperative quality of life. METHODS: Seven patients diagnosed with PNETs underwent DPPHR from January 2011 to December 2021 at our institution. We investigated the clinical relevance of DPPHR based on the patients' clinicopathological findings. RESULTS: The median operative time was 492 min, and the median blood loss was 302 g. Postoperative complications were evaluated according to the Clavien-Dindo classification, and postoperative intra-abdominal bleeding was observed in one patient. Pathological examination revealed a World Health Organization classification of G1 in six patients and G2 in one patient. Microvascular invasion was observed in two patients (29%); however, no patients developed lymph node metastasis or recurrence during the follow-up period. A daughter lesion was observed near the primary tumor in one patient. All patients achieved curative resection, and no tumor specimens showed positive margins. CONCLUSIONS: DPPHR facilitates anatomical resection of the pancreatic head in patients with PNETs as well as detailed pathological evaluation of the resected specimen. Therefore, this surgical procedure is an acceptable alternative to pancreaticoduodenectomy or enucleation for patients with PNETs.
MISC
939-
胆と膵 32(5) 379-383 2011年5月
-
HEPATO-GASTROENTEROLOGY 58(107) 1018-1021 2011年5月 査読有り
-
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES 18(2) 287-291 2011年3月
-
胆道 25(5) 809-814 2011年<b>要旨:</b>膵・胆管合流異常(以下,合流異常)は,日本膵・胆管合流異常研究会の診断基準で,「解剖学的に膵管と胆管が十二指腸壁外で合流する先天性の奇形をいう.」と定義されている.合流異常には,肝外胆管形態より1)胆管拡張型,2)胆管非拡張型の2つの型がある.胆管拡張型の標準術式は拡張胆管切除,肝管腸吻合術(分流手術)である.術後の合併症として肝内胆管結石形成,遺残膵内胆管結石形成などが問題となっている.胆管非拡張型の場合は,胆嚢を摘出することは合意が得られている.しかし,肝外胆管切除について統一した見解が得られていない.共通管もしくは副膵管の拡張を認める例や複雑な合流形態の例では,膵石(蛋白栓)や膵炎を合併しやすいことから,これらに対する治療について報告されている.<br> 本稿では,先天性胆道拡張症・合流異常に対する治療について概説した.<br>
-
胆道 25(4) 645-650 2011年<b>要旨:</b>腹腔鏡手術は体壁破壊を最小にすることで,患者の術後QOLを大きく向上させた.一方,腹腔鏡手術は手術操作の自由度が低いこと,2次元画像であることが欠点であり,術者のストレスを増大させた.腹腔鏡支援ロボットであるda Vinci Surgical systemの利点は,3次元ハイビジョン,7自由度の関節機能,術者の動きを調整可能なscaling機能,手の震えを除去するfiltering機能,拡大視効果である.これらの機能により,繊細な手術操作もストレスなくできるようになった.しかし,開腹手術と比して手術時間が長いこと,また,通常の腹腔鏡下手術と比べると,da Vinci装着に時間を有することが今後の課題であるが,経験を積み重ね工夫することにより,克服できると考える.胆道領域におけるロボット支援腹腔鏡下手術は近い将来,standardな手技となると思われる.<br>
-
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES 17(6) 792-797 2010年11月
-
日本臨床外科学会雑誌 71(増刊) 346-346 2010年10月
-
日本臨床外科学会雑誌 71(増刊) 461-461 2010年10月
-
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES 17(5) 688-691 2010年9月
-
胆道 24(3) 446-446 2010年8月
-
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES 17(4) 523-526 2010年7月
-
日本肝胆膵外科学会・学術集会プログラム・抄録集 22回 240-240 2010年5月
-
日本肝胆膵外科学会・学術集会プログラム・抄録集 22回 379-379 2010年5月
書籍等出版物
5講演・口頭発表等
448共同研究・競争的資金等の研究課題
1-
日本学術振興会 科学研究費助成事業 2023年4月 - 2026年3月